How the organs of multicellular organisms develop to a pre-defined size is a fundamental question in biology, but little is known about the underlying mechanisms. In the past decade, the Hippo pathway has been revealed to play a crucial role in organ size control (reviewed by Zhao et al., 2010a) . Furthermore, studies of mouse models and clinical samples have demonstrated the significance of the Hippo pathway for the development of human cancers (Dong et al., 2007; Steinhardt et al., 2008; Xu et al., 2009; Zhou et al., 2009 ). Thus, the Hippo pathway has attracted broad interest in both basic and clinical research efforts. Here, we summarize the current understanding of the composition, regulation and function of the Hippo tumor-suppressor pathway, with emphasis on the interplay of Hippo signaling with other signaling pathways.
Organization of the Hippo pathway
Most of the Hippo pathway components are highly conserved across species and can be categorized into the following groups.
Core components of the Hippo pathway Lats1 and Lats2 (collectively referred to as Lats below) are nuclear Dbf2-related (NDR) family protein kinases homologous to Drosophila Warts (Wts) (Justice et al., 1995; Xu et al., 1995) . They are activated by association with the highly homologous scaffold proteins Mps one binder kinase activator-like 1A (MOBKL1A) and 1B (MOBKL1B), which are collectively referred to as Mob1 below and are homologues of Drosophila mob as tumor suppressor (Mats) (Chow et al., 2010; Hergovich et al., 2006; Lai et al., 2005; Wei et al., 2007) . Lats kinases are also activated by phosphorylation by the STE20 family protein kinases Mst1 and Mst2 (collectively referred to as Mst below), which are homologues of Hippo (Hpo) in Drosophila (Harvey et al., 2003; Jia et al., 2003; Pantalacci et al., 2003; Udan et al., 2003; Wu et al., 2003) . The requirement for Mst in Lats activation might be cell-type dependent, as ablation of Mst1 and Mst2 in mouse embryonic fibroblast (MEF) cells does not affect Lats phosphorylation (Zhou et al., 2009) 
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Liver double KO
Liver enlargement, tumor formation and oval cell accumulation. (Lu et al., 2010; Song et al., 2010; Zhou et al., 2009 ) KO Lethal around E18.5 with hyperplasia and differentiation defects. (Lee et al., 2008) Liver KO Liver enlargement and single formation of tumors probably from oval cell origin. Lu et al., 2010) Lats1 KO Soft-tissue sarcoma and ovarian tumors. (St John et al., 1999) 
Lats2 KO
Lethal before E12.5 with proliferation arrest, elevated apoptosis and genomic instability. (McPherson et al., 2004) 
MOBKL1A MOBKL1B
Mutation in skin melanoma. Attenuated expression in colorectal cancer. (Kosaka et al., 2007; Lai et al., 2005) 
Liver and intestine transgenic
Enlarged organ size, cancer development and expansion of progenitor cells. (Camargo et al., 2007; Dong et al., 2007) KO Embryonically lethal at around E8.5 with defects in yolk sac vasculogenesis, chorioallantoic fusion and embryonic axis enlongation. 
YAP
Genomic amplification, elevated expression and increased nuclear localization in several human cancers. An independent prognostic marker for human hepatocellular carcinoma. (Baldwin et al., 2005; Fernandez et al., 2009; Modena et al., 2006; Overholtzer et al., 2006; Snijders et al., 2005; Xu et al., 2009; Zender et al., 2006; Zhao et al., 2007) 
Mst1 Mst2
Reduced Mst1 and Mst2 activity in 70% of human hepatocellular carcinomas. Reduced expression in soft-tissue sarcoma and colorectal cancer. (Minoo et al., 2007; Seidel et al., 2007; Zhou et al., 2009) 
Sav1
Mutation in a human renal cancer cell line. (Tapon et al., 2002) 
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Downregulation of Lats1 and Lats2 in several human cancers. (Chakraborty et al., 2007; Cho et al., 2009; Hisaoka et al., 2002; Jiang et al., 2006; Jimenez-Velasco et al., 2005; Takahashi et al., 2005; Voorhoeve et al., 2006) Mats enhanced Mob1-Lats interaction (Praskova et al., 2008 (Zhang et al., 2010) . However, in a study that used cultured cells from Mer knockout livers, Mer-deficiency-induced overproliferation is not inhibited by YAP knockdown using small hairpin RNA (shRNA) and, in contrast to YAP overexpression, ablation of Mer alone in adult mice is insufficient to induce liver tumors (Benhamouche et al., 2010) , which suggest that the regulation of YAP by Mer might be context dependent. In this study, Mer-deficiency-induced over-proliferation was attributed to aberrant epidermal growth factor receptor (EGFR) activity (Benhamouche et al., 2010) . In Drosophila, the protein Kibra, which interacts with Mer and Ex, might positively regulate the Hippo pathway by mediating or promoting the interaction of Mer and Ex with Hpo and Sav (Baumgartner et al., 2010; Genevet et al., 2010; Yu et al., 2010) . Many other Drosophila proteins were shown to regulate the activity of the Hippo pathway (reviewed by Grusche et al., 2010) , including the proteins Fat, Dachsous (Ds), Four-jointed (Fj) and Lowfat (Lft) (Bennett and Harvey, 2006; Cho et al., 2006; Mao et al., 2009; Rogulja et al., 2008; Silva et al., 2006; Simon et al., 2010; Tyler and Baker, 2007; Willecke et al., 2006; Willecke et al., 2008) , which regulate planar cell polarity. Other regulatory proteins include the LIMdomain-containing protein dJub (Das Thakur et al., 2010) , the cell apical proteins atypical protein kinase C (aPKC) and Crumbs (Crb), and the basolateral Scribble-discs large (Dlg)-lethal giant larvae (Lgl) protein complex (Grzeschik et al., 2010; Ling et al., 2010; Robinson et al., 2010) . These proteins are conserved in mammals, although their function in regulating the mammalian Hippo pathway is yet to be determined. It will be interesting to further investigate the relationship between cell polarity proteins and the Hippo pathway, which might link cell architecture to cell proliferation and apoptosis.
The mammalian tumor-suppressor protein Ras association family member 1A (RASSF1A) interacts with Mst through SARAH (for SavRassf-Hpo) domains present in both proteins, resulting in Mst activation. By contrast, RASSF1A was shown to inhibit Mst in vitro (Guo et al., 2007; Oh et al., 2006; Praskova et al., 2004) . Moreover, Drosophila RASSF antagonizes Hpo by competing with Sav for Hpo binding (Polesello et al., 2006) . Detailed investigations of the molecular mechanisms underlying Mst activation by RASSF1A and further studies of other RASSF family members might help to resolve this apparent discrepancy between studies performed in Drosophila and mammalian cells.
Downstream effectors of the Hippo pathway
Lats and Wts kinases are known to phosphorylate the downstream effectors YAP, the YAP paralog transcriptional coactivator with PDZ-binding motif (TAZ) and Yorkie (Yki), which results in the inhibition of their activity as transcription coactivators in mammals and in Drosophila (Huang et al., 2005; Lei et al., 2008; Zhao et al., 2007) , as discussed in further detail below. The major target transcription factors of YAP, TAZ and Yki are the four proteins of the TEA-domain-containing (TEAD) family (TEAD1-TEAD4), which correspond to a single homologue in Drosophila, Scalloped (Sd) (Goulev et al., 2008; Wu et al., 2008; Zhang, H. et al., 2009; Zhang et al., 2008; Zhao et al., 2008) . Crystallographic data revealed that the N-terminal TEAD-binding domain of YAP wraps around a globular structure formed by the C-terminal domains of TEAD1, 2 and 4 Li et al., 2010; Tian et al., 2010) . YAP also binds to other transcription regulators, such as Runt-related transcription factor (RUNX), the cytoplasmic domain of ErbB4 and p73, but none of these interactions has been shown so far to mediate the function of YAP in organ size control and tumorigenesis (Komuro et al., 2003; Omerovic et al., 2004; Strano et al., 2001; Yagi et al., 1999) .
Yki induces the expression of cyclin E (cycE), Drosophila inhibitor of apoptosis 1 (diap1) and the microRNA bantam (Huang et al., 2005; Nolo et al., 2006; Thompson and Cohen, 2006) . However, YAP, together with TEAD, induces the expression of another set of genes, including the connective tissue growth factor (CTGF) and Gli2 (Fernandez et al., 2009; Zhao et al., 2008) .
YAP also induces expression of the diap1 homologues baculoviral IAP repeat-containing 5 and 2 (Birc5 and Birc2) and of cytokines such as fibroblast growth factor 1 (FGF1) and amphiregulin (AREG) (Dong et al., 2007; Hao et al., 2008; ). However, the transcription factors responsible for the expression of these genes have thus far remained elusive.
YAP, TAZ and Yki are phosphorylated and inhibited by the Hippo pathway
Phosphorylation and inhibition of the transcription coactivators YAP, TAZ and Yki by the Lats and Wts kinases are crucial events within the Hippo signaling pathway, as discussed below.
Phosphorylation leads to cytoplasmic retention of YAP, TAZ and Yki
Lats phosphorylates five consensus HXRXXS motifs in YAP (Zhao et al., 2010b) and this results in YAP inhibition. Phosphorylation of YAP Ser127 and of the corresponding sites in Yki and TAZ generates a protein-binding motif for the 14-3-3 family proteins, which, upon binding by a 14-3-3 protein, leads to their cytoplasmic retention (Lei et al., 2008; Oh and Irvine, 2008; Zhao et al., 2007) . This results in these transcription coactivators becoming separated from their target gene promoters. Mutation of Ser127 in YAP or of the equivalent residues in TAZ and Yki is thus able to enhance their function as transcription coactivators (Lei et al., 2008; Zhao et al., 2007) .
Phosphorylation leads to YAP degradation
In addition to promoting its translocation, phosphorylation by Lats also destabilizes YAP. Phosphorylation of YAP Ser381 primes it for subsequent phosphorylation by another kinase, possibly casein kinase 1 (CK1d/e). This activates a phosphorylation-dependent degradation motif termed the phosphodegron and results in the recruitment of the E3 ubiquitin ligase b-TRCP, thereby leading to polyubiquitylation and subsequent degradation of YAP (Zhao et al., 2010b) . This Hippopathway-dependent destabilization of YAP is supported by the observation of an increase in YAP protein level that accompanies decreased YAP phosphorylation in the liver of mice in which Mst1 and Mst2 have been knocked out . This mechanism, which provides the cell with a means to inhibit YAP on a long-term basis, is conserved in TAZ, but not in Yki, which lacks a residue equivalent to Ser381. It is worth noting that phosphorylation of YAP Tyr391, which is close to the phosphodegron, by the tyrosine kinase c-Abl results in YAP stabilization (Levy et al., 2008) . It is unclear whether phosphorylation at Tyr391 stabilizes YAP through modulation of Ser381-phosphorylation-mediated YAP degradation.
Hippo pathway components can bind to and inhibit Yki Apart from phosphorylation-dependent inhibition, components of the Hippo pathway can also inhibit Yki in a phosphorylationindependent manner. The WW domain in Yki can interact with the PPXY motifs that are present in the Hippo pathway components Ex, Wts and Hpo (Badouel et al., 2009; Oh et al., 2009) . These interactions might inhibit Yki activity by sequestering it in the cytoplasm, thus adding another layer of complexity to Yki regulation.
The interplay between the Hippo pathway and other signaling pathways
Organ development is a coordinated process of increase in organ size and morphogenesis that is mediated by extensive crosstalk between signaling pathways. Pioneer studies have now begun to reveal the interplay of the Hippo pathway with other established signaling cascades, as discussed below.
The Hippo pathway and TGF-b signaling Transforming growth factor (TGF)-b and bone morphogenetic protein (BMP) signaling play crucial roles in morphogenesis and tumorigenesis through the activation of Smad proteins as their downstream nuclear effectors. In developing Drosophila wings, clonal activation of TGF-b family member Decapentaplegic (Dpp) signaling by expression of an activated form of the Dpp receptor leads to activation of the expression of Hippo pathway target genes around the clone edge, presumably by modulating the expression and localization of the upstream Hippo pathway components Fj, Ds and Dachs (Rogulja et al., 2008) . The link between Hippo and TGF-b or BMP signaling might be more direct in mammals, as phosphorylation of Smad1 following BMP stimulation enhances the interaction of Smad1 with the WW domains of YAP, which promotes the self-renewal capability of mouse embryonic stem cells (ESCs) (Alarcon et al., 2009) . Interestingly, TAZ has been shown to interact with Smad2 and Smad3 through its coiled-coil region, and to be important in maintaining the nuclear localization of Smad2 and Smad3 as well as the expression of their target genes in response to TGF-b signaling and, thus, in the maintenance of human ESC self-renewal (Varelas et al., 2008) . However, it is unclear how YAP and TAZ achieve binding specificity for only certain Smads and whether these interactions contribute to the control of organ size and tumorigenesis.
The Hippo pathway and Wnt signaling Wnt signaling plays an important role in tissue development. Aberrant activation of the Wnt pathway has been implicated in driving the formation of various human cancers, in particular those of the digestive tract (Barker and Clevers, 2006) . Stimulation of cell-surface receptors by Wnt ligands results in the disassembly of the so-called 'b-catenin destruction complex', an axin-APC-GSK3-CK1-b-catenin complex that normally promotes the proteolytic degradation of b-catenin, which is followed by nuclear accumulation of b-catenin and activation of the Wnt target genes. Interestingly, according to a recent report, cytoplasmic TAZ negatively regulates the Wnt-b-catenin signaling pathway by binding to dishevelled (Dvl) 2, 1 and 3, which might interfere with Dvl phosphorylation, an event that precedes b-catenin stabilization and activation (Varelas et al., 2010) . Mst and Lats can also inhibit Wnt signaling, presumably by promoting the phosphorylation of TAZ and its subsequent cytoplasmic localization. Consistent with this observation, wts or hpo mutants have elevated levels of Armadillo, the b-catenin ortholog in Drosophila (Varelas et al., 2010) . Moreover, TAZ knockout mice develop renal cysts that lead to end-stage renal disease (Hossain et al., 2007; Makita et al., 2008; Tian et al., 2007) . Interestingly, excessive Wnt signaling in mouse kidneys also yields polycystic kidney lesions (Saadi-Kheddouci et al., 2001; Sansom et al., 2005) . These data suggest that inhibition of Wnt signaling by TAZ could be the cause of TAZ-ablation-induced mouse kidney cystic disease, whose underlying mechanism was hitherto unknown. An interesting question that remains is whether and to what extent cytoplasmic TAZ-mediated inhibition of Wnt signaling can contribute to the function of the Hippo pathway in regulating organ size and cancer. In this context, it is worth noting that an independent report showed that YAP overexpression in mouse intestinal epithelium increased total and nuclear b-catenin levels, presenting further evidence for activation of Wnt signaling by Hippo pathway components (Camargo et al., 2007) .
The Hippo pathway and Notch signaling Notch signaling is another important signaling pathway involved in metazoan development and implicated in a wide range of human disorders, including cancer. Upon ligand binding, Notch signaling is activated by a series of proteolysis events, which release an active intracellular Notch fragment (NICD) that translocates to the nucleus to activate the expression of its target genes, such as the hairy and enhancer of split (HES) genes and myc. Interestingly, mutations of Hippo pathway components largely suppress normal Notch signaling in posterior follicle cells during Drosophila oogenesis, as indicated by compromised Notch target gene expression (Genevet et al., 2010; Meignin et al., 2007; Polesello and Tapon, 2007; Yu et al., 2010) . In hpo, wts or mer;ex double-mutant clones in Drosophila eye and wing imaginal disc, Notch abnormally accumulates at the cell apical region and the overall Notch activity is reduced (Genevet et al., 2009; Maitra et al., 2006) . This suggests that Notch accumulation at the cell apical region owing to compromised Hippo signaling might result in the inhibition of Notch signaling as a result of reduced NICD internalization (Genevet et al., 2009) . In mammals, a connection between YAP and Notch signaling has been observed in an intestine-specific YAP transgenic mouse model, in which expression of YAP results in the rapid stimulation of HES expression; this is indicative of activated Notch signaling. Moreover, inhibition of Notch signaling by a -secretase inhibitor largely overcomes YAP-induced dysplasia and differentiation (Camargo et al., 2007) . It is currently unclear whether Yki is also involved in the crosstalk between Drosophila Hippo and Notch signaling. Deciphering the detailed mechanisms underlying the interplay between Notch and Hippo signaling requires further studies.
The Hippo pathway and Hedgehog signaling The Hedgehog pathway is a major regulator of cell differentiation, tissue polarity and cell proliferation. Interestingly, overexpression of YAP and TEAD1 was observed specifically in subsets of medulloblastomas that were driven by activated Sonic hedgehog (Shh) or Wnt signaling for their formation (Fernandez et al., 2009) , suggesting that crosstalk exists between YAP and Hedgehog signaling as well as between YAP and Wnt signaling (as discussed above). Interestingly, YAP was indeed activated when neuron precursors, which are believed to be the cell of origin for Shh-dependent medulloblastomas (Fernandez et al., 2009) , were treated with Shh. Here, activation of YAP was shown to be the result of increased transcription of its mRNA and of increased protein stabilization and nuclear accumulation, indicating a complex underlying mechanism. It has also been suggested that YAP, together with TEAD1, can directly induce the expression of Gli2, a downstream effector of Shh signaling (Fernandez et al., 2009 The Hippo pathway links regulation of organ size to cancer development The Hippo pathway not only regulates organ size, but also plays an important role in the development of human cancers. This might be due to either its ability to regulate cell proliferation and apoptosis or, alternatively, its functions in the renewal and expansion of stem cells and progenitor cells, as discussed below.
The Hippo pathway and organ size control In Drosophila, mutation of the Hippo pathway results in increased organ size; the ectopic expression of its components leads to an opposite phenotype of reduced organ size, similar to what has been observed for Yki mutations (for a review, see Kango-Singh and Singh, 2009 ). These alterations of organ size are attributed to a combinatory effect of changes in both cell proliferation and apoptosis (for a review, see Kango-Singh and Singh, 2009) . A function of the Hippo pathway in controlling organ size was also confirmed in mammals. For example, liver-specific expression of YAP in transgenic mice leads to an up to fourfold increase in liver size and to the development of liver tumors at a later stage (Camargo et al., 2007; Dong et al., 2007) . Similar phenotypes have been observed in liver-specific knockouts of Mst1 and Mst2, Sav1 or Mer (Benhamouche et al., 2010; Lee et al., 2010; Lu et al., 2010; Song et al., 2010; Zhang et al., 2010; Zhou et al., 2009) . Taken together, these genetic studies present convincing evidence that the Hippo pathway is indeed a key regulator of organ size.
The Hippo pathway and cancer Accumulating evidence indicates that the Hippo pathway also plays important roles in cancer development. Mer is a well-established human tumor suppressor gene, the mutation of which causes lesions in the nervous system, eyes and skin (Asthagiri et al., 2009 ). Mutation of Mob1 and Sav1, two other Hippo pathway core components, has also been observed in a human renal cancer cell line and in skin melanoma, respectively (Lai et al., 2005; Tapon et al., 2002) . Other Hippo pathway components have also been reported to show abnormal expression levels in cancer samples. For example, RASSF1A is one of the most commonly silenced genes in human cancers, owing to hypermethylation of its promoter (Agathanggelou et al., 2005) , and the expression of Mst and Lats is downregulated in several human cancers (Jiang et al., 2006; Minoo et al., 2007; Seidel et al., 2007) . By contrast, TAZ was found to be upregulated in breast cancers, especially in invasive ductal carcinomas (Chan et al., 2008) . Furthermore, YAP gene amplification was found in various cancers, including hepatocelluar carcinoma (HCC) (Overholtzer et al., 2006; Zender et al., 2006) . Consistent with these findings, increased protein levels of YAP and nuclear accumulation was also observed in several cancers (Dong et al., 2007; Steinhardt et al., 2008; Zender et al., 2006; Zhao et al., 2007) . Recently, a clinical study identified YAP as a predicting factor for HCC-specific disease-free survival and overall survival through assessing its protein level and nuclear localization (Xu et al., 2009 ).
The role of the Hippo pathway in stem cells
Recent studies demonstrated previously unknown functions of YAP and TAZ in the renewal and proliferation of ESCs and organspecific progenitor cells. For instance, YAP is inactivated during ESC differentiation and activated in induced pluripotent stem (iPS) cells (Lian et al., 2010) . In addition, knockdown of YAP in murine D3 ESCs leads to loss of pluripotency. By contrast, ectopic expression of YAP prevents ESC differentiation (Lian et al., 2010) , but the exact underlying mechanism is not clear. Intriguingly, knockdown of TAZ also leads to differentiation of human CA1 stem cells (Varelas et al., 2008) , but it is not clear how these functions of YAP and TAZ are coordinated to maintain 'stemness'. YAP also plays a role in tissue-specific progenitor cells. For instance, in mouse intestines, expression of endogenous YAP is restricted to the progenitor cell compartment, which expands when YAP is overexpressed (Camargo et al., 2007) . Consistent with this observation, activation of YAP and TEAD also causes marked expansion of neural progenitor cells in a chicken neural tube model (Cao et al., 2008) .
In the past few years, it has been suggested that cancer could arise from a small population of cancer cells that have stem-cell-like properties, the so-called cancer stem cells. A function of YAP and thus of the Hippo pathway in cancer stem cells is also emerging. In a subtype of medulloblastomas, YAP expression was found to be strikingly high in the perivascular cancer stem cell compartment, suggesting a role for YAP in maintaining cancer stem cells (Fernandez et al., 2009 ). In addition, double knockout of Mst1 and Mst2, knockout of Sav1 or knockout of Mer in mice liver also induces abundant accumulation of oval cells, the adult liver stem cells, which possibly are the cell type of origin for subsequent tumor formation (Benhamouche et al., 2010; Lee et al., 2010; Lu et al., 2010; Zhang et al., 2010) . Further investigations are necessary to address how regulation of cell proliferation, apoptosis and stem cell self-renewal contributes to the functions of the Hippo pathway in organ size control and cancer development.
Perspectives
Over the past decade, our understanding of the Hippo signaling pathway has progressed rapidly, and has lead to the delineation of the Hippo pathway kinase cascade and insights into the regulation of its downstream effectors -YAP, TAZ and Yki. Functions of the Hippo pathway in controlling organ size and in cancer development have been described, and recent pioneering work has revealed insights into the interplay of the Hippo pathway with other signaling cascades. However, many key questions remain, including but not limited to the identity of the upstream signals of the Hippo pathway, the mechanisms of the interplay between the Hippo pathway and other signaling pathways, the existence of as-yet-unidentified Hippo pathway effectors, and the dysfunction of the Hippo pathway in human cancers. Answers to these questions will further advance our understanding of normal development and might help to develop new cancer therapies.
